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Introduction 
Prostate cancer is a unique and controversial disease. The 
management of which is dominated by a series of unanswered 
questions. There is uncertainty as to the value of screening and 
the treatment of localised disease. The prevalence in the western 
world is rising. Epidemiology of cancer prostate is not known 
exactly in India but it certainly appears to be the most common 
malignancy of the male genital organs.  ICMR statistics from 
National Cancer Registry (1997) reveals that prostate cancer is the 
fifth most common cancer in men in Bangalore, Chennai and in 
Bombay.  Over the past two decades significant strides have been 
made in our understanding of the biology of the disease.  
Diagnosis of prostate cancer at an early stage, when the lesion is 
localized and curable, followed by effective, definitive therapy, is 
essential to reduce the number of deaths from this disease.1 
Definitive studies to prove that early detection and treatment lower 
the mortality rate have been initiated.2,3 There is no direct evidence 
to suggest the effectiveness of such treatment.  The tools used for 
early detection are prostate specific antigen (PSA) and digital 
rectal examination (DRE). Transrectal ultrasound (TRUS) guided 
biopsy is considered as the gold standard to diagnose malignancy, 
if the PSA or DRE is abnormal. The positive predictive value of 
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PSA is between 30 and 42 %.4 Positive predictive value of DRE is 
between 11 and 26 %.5 The tools used for early detection are 
neither sensitive nor specific. Informed consent is mandatory for 
early detection for the above reasons. Those in favour of  
screening for prostate cancer, irrespective of symptoms, 
recommend an annual serum PSA test and DRE for men between 
the ages of 50 and 70 years.6 Because of the natural history of the 
disease, early detection is not recommended for men with a life 
expectancy less than 10 years. For men at high risk for prostate 
cancer, such as black North Americans and those with a family 
history of prostatic carcinoma, the age range during which testing 
is recommended is extended to 40 to 70 years.7 
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Background 
Patients should be aware of the potential benefits and risks related 
to testing for early detection of prostate cancer. Are Indian men 
willing for early detection of prostate cancer like men in the 
Western world? Are the tools used for early detection reliable?  
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     Objectives 
1. Patient’s perspective on early detection of prostate cancer after 
an informed consent. 
2. To determine whether informed consent was obtained for PSA 
testing by their physicians prior to the test. 
3. Positive predictive value of PSA and DRE in this study.  
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Review of literature 
Digital rectal examination: 
DRE is the simplest, least expensive and most widely used 
method for detecting prostate cancer. However, it is highly 
subjective.8 Because of this and the differing levels of skill of 
examiners, many men may be excluded from further assessment 
because of DRE findings that mimic benign or age-related 
changes. Before the availability of PSA, DRE was used for early 
detection of prostate cancer. Positive predictive value of PSA 
varies with age and race.9 DRE may also fail to detect cancers 
which are inaccessible to palpation but contribute to 25% of 
prostatic malignancy10 in select group of patients. In addition, 50% 
of clinically palpable prostatic cancers will either not be amenable 
to complete surgical excision or will demonstrate local extension 
before such an attempt.11 Thus, although DRE constitutes an 
important diagnostic tool, it may fail to identify a substantial 
proportion of clinically significant cancers at an organ confined, 
curable stage. Further investigation is recommended for men with 
DRE findings that is suspicious of cancer. 
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Serum prostate-specific antigen test: 
Testing for serum PSA, a normal serine protease produced by the 
prostate epithelium, has replaced the relatively insensitive prostatic 
acid phosphatase test. The function of PSA is to lyse proteins 
derived from the seminal vesicle; it thus causes semen 
liquefaction. Conditions that causes elevated PSA include prostate 
cancer, benign prostatic hyperplasia and prostatitis.12 Urinary 
retention, prolonged urethral catheterization, recent cystoscopy or 
prostatic biopsy may also increase circulating PSA levels 
temporarily.13 DRE and ejaculation have not been associated with 
clinically significant elevation of PSA. Drugs that affect the 
conversion of testosterone to dihydrotestosterone, such as 
finasteride, reduce circulating serum PSA by about 50%.14 Serum 
PSA levels can be determined with either a polyclonal or a 
monoclonal assay (The antibodies used in the polyclonal assay 
react with several epitopes on the PSA molecule, whereas a 
monoclonal assay is directed against one specific epitope). At 
present monoclonal PSA assays are most commonly used assays. 
The normal range of PSA determined from the polyclonal assay is 
0 to 2.5 ng/mL,15 whereas the normal range determined by a 
monoclonal assay is 0 to 4.0 ng/mL. The polyclonal assay is 
currently performed in only a few laboratories, and its use will likely 
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be further restricted with the advent of newer forms of PSA testing 
that rely on monoclonal measurement of the concentration of free 
and complexed serum PSA. 
Although serum PSA is currently the best clinically available 
tumour marker, it is not specific to prostate cancer.16 For example, 
elevation of PSA occurs in 20% to 50% of men with benign 
prostatic hyperplasia. The test’s limitations in sensitivity also 
account for the discovery of cancer on TRUS-guided core biopsy 
in as many as 10% - 15% of men with PSA values between 0 and 
4.0 ng/mL. However, as many as 2 out of 3 men with PSA values 
greater than 10 ng/mL will be found to have cancer regardless of 
DRE findings.17 The current recommendation is that men with 
serum PSA levels above 4 ng/mL be referred for further evaluation 
by an urologist. In general, the next diagnostic test consists of 
TRUS-guided needle biopsy of the prostate. The limitations in 
sensitivity and specificity of serum PSA testing have led to 
attempts to improve its clinical usefulness. Other concepts utilized 
to increase the validity of PSA include PSA density, age-specific 
PSA ranges and PSA velocity, as well as measurements of the 
proportions of free and bound PSA. 
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 PSA density: 
PSA density, the initial refinement of the PSA test, is an index 
calculated by dividing total serum PSA by the volume of the 
prostate, measured ultrasonically by TRUS. In the absence of 
cancer, prostatic volume is directly proportional to circulating 
serum PSA.18 Benign prostatic hyperplasia is associated with, on 
average, only 0.26 ng/mL PSA per gram of tissue, whereas cancer 
results in a density 10-fold higher.19 Any PSA value greater than 
that predicted by gland volume should raise a suspicion of prostate 
cancer. 
The optimal cut-off value for PSA density is a trade-off between 
sensitivity and biopsy rate. A low cut-off value yields high 
sensitivity and better detection but corresponds to a higher rate of 
potentially unnecessary biopsies. The opposite is true with a 
higher cut-off value. Because 2 out of 3 men with a PSA level 
between 4 and 10 ng/mL are found by prostate biopsy not to have 
cancer, PSA density is used to identify those who should not 
undergo unnecessary biopsy. Because a PSA density of less than 
0.15 ng/mL per cubic centimetre of prostatic tissue is associated 
with a low likelihood of cancer, this the most widely used cut-off 
point.20 The suggested benefit of PSA density derives from the fact 
that a significant number of men are spared biopsy even though 
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they have PSA levels above 4.0 ng/mL. Although this was initially 
reported not to result in lack of detection of clinically significant 
cancers,20 more recent analyses have demonstrated that the 
diagnostic accuracy of PSA density is limited because of the 
inherent limitations of TRUS in determining prostate volume.21,22 In 
addition, inadequate sampling in men with prostates larger than 50 
to 60 cm3 may have led to false-negative biopsy results, which 
may have further undermined the validity of initial PSA density 
results.17,23,24 On the basis of these findings, the use of PSA 
density in clinical practice has declined substantially. Finally, given 
the minimal morbidity associated with biopsy, the excellent level of 
patient tolerance associated with this procedure and the 
requirement to perform TRUS gland volumetry in order to calculate 
PSA density, performing an ultrasonic assessment without 
concomitant biopsy is of questionable benefit. 
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Age-specific PSA ranges: 
Age-specific PSA ranges, which rely on age instead of TRUS 
volumetry, are based on the assumption that older men have 
larger prostates and, therefore, may have higher serum PSA levels 
not associated with carcinoma. More specifically, the introduction 
of age specific PSA ranges was aimed at increasing the sensitivity 
of PSA testing in younger men and increasing the specificity of 
such testing in older men.25 The reference ranges are given in 
Table 1. 
Table 1: Reference ranges for age specific PSA levels 
Age range in years Upper limit of PSA in ng/mL 
40-49 2.5 
50-59 3.5 
60-69 4.5 
70-79 6.5 
 
The adoption of these age-specific maximum PSA values has 
increased the number of biopsies performed in younger men and 
decreased the number performed in older men. The rationale was 
to detect more early cancers in the men who could benefit most 
from definitive therapy, while limiting detection of cancers of 
questionable clinical significance in men with shorter life 
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expectancy. An additional advantage of age-specific PSA over 
PSA density is the fact that ultrasonic gland measurement and the 
associated cost can be avoided. At present, because of the limited 
data regarding age-specific PSA and the lack of precise guidelines 
for its clinical use, its role in the early detection of prostate cancer 
remains unclear. 
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PSA velocity: 
A further refinement of the single PSA measurement is serial 
measurements and trend analysis.26 The term “PSA velocity” refers 
to the rate of change of serum PSA level over time. Early 
investigators of this concept demonstrated significant differences 
in PSA velocity between men with benign prostatic hyperplasia 
and those with prostate cancer. These differences were detectable 
as early as 9 years before prostate cancer was diagnosed. Others 
have confirmed the benefit of PSA velocity over a single PSA 
measurement.27 However; at least 3 consecutive measurements 
are required for reliable calculation of PSA velocity. The optimal 
interval between these measurements has not yet been 
determined, but 6 months is currently recommended. Therefore, a 
follow-up of at least 18 months is necessary to achieve the 
maximum benefit of PSA velocity in prostate cancer detection. 
Problems with PSA velocity include important physiological and 
intra-individual variability, reportedly as high as 23.5%.28 
Therefore, if 2 samples are obtained from the same person 2 to 3 
weeks apart, the serum PSA level may be 3.5 ng/mL for the first 
test and 4.3 ng/mL for the subsequent analysis, without any 
change in the condition of the prostate itself. Similarly, 
methodological variation in PSA tests may range from 10% to 
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45%.29 Thus, if the same serum sample is subjected to analysis by 
2 different assays, the PSA level may be 4.0 ng/mL with one assay 
and between 4.4 and 5.8 ng/mL with the other. These variations 
may preclude effective use of PSA velocity in large-scale 
screening. A potential benefit can be derived from PSA velocity in 
men with serum PSA values below 4 ng/mL who harbour prostate 
cancer. In men with normal PSA values, an annual increase in 
excess of 20%30 or PSA velocity exceeding 0.75 ng/mL annually31 
is suggestive of prostate cancer and indicates the need for 
urological evaluation. Determining PSA velocity in men with 
traditional serum PSA values above the normal upper limit of 4 
ng/mL is of little additional benefit, given that a urological 
assessment is warranted regardless of the rate of increase in PSA 
level. 
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Percentage of free PSA: 
In order to further enhance the sensitivity and specificity of PSA 
testing, the measurement of free and bound forms of PSA in the 
serum has been proposed. In the serum, PSA complexes 
predominantly with the alpha-1 subunit of antichymotrypsin and the 
alpha-2 subunit of macroglobulin. Most commercially available 
complexed-PSA assays determine the concentration of the PSA–
antichymotrypsin complex. Nearly all of the remaining circulating 
PSA is in its free form. The proportion of free PSA is known to be 
lower in those with prostate cancer than in those with benign 
prostatic hyperplasia; thus, the likelihood of prostate cancer 
increases with decreasing free PSA. In contrast, the proportion of 
free PSA increases with advancing age and increasing prostate 
volume. Studies have identified the proportion of free PSA as an 
independent predictor of prostate cancer, superior to both DRE 
and total PSA level. Likewise, the proportion of free PSA has a 
superior diagnostic accuracy relative to PSA density.32 In a  large-
scale study, determination of the proportion of free PSA would 
have maintained a specificity of 90% and would have eliminated 
the need for biopsy in 31.3% of men with benign DRE findings and 
serum PSA levels between 4 and 10 ng/mL.33 At present, only free 
PSA offers high specificity and adequate sensitivity. Consequently, 
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it is the most clinically valuable and most promising modification of 
the PSA test. Several recommendations for cut-off levels have 
emerged. As with all other forms of PSA tests, there is a trade-off 
between sensitivity and specificity. A cut-off of 23.4% free PSA 
eliminated 31% of biopsies while maintaining 90% sensitivity.34 In 
men with serum PSA values between 2.6 and 4.0 ng/mL, a cut-off 
point of 27% eliminated 18% of biopsies with a sensitivity greater 
than 90%. Therefore, proportion of free PSA appears capable of 
enhancing the sensitivity and specificity of traditional PSA testing, 
even in men with normal serum PSA levels.34 
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Diagnostic limitations of PSA testing and its enhanced forms: 
Although results obtained by measuring serum PSA levels are 
superior in terms of prostate cancer detection to those obtained 
with any other clinically available tumour marker, the traditional 
total PSA value and each of its enhanced forms share several 
limitations. The principal concern is that although diagnostic 
accuracy has improved with each of the modifications to total 
serum PSA measurement, none of the forms is specific for 
prostate cancer. Each requires a trade-off in specificity for 
increased sensitivity and vice versa. This trade-off appears to be 
most advantageous with proportion of free PSA. Currently, 
proportion of free PSA appears to be the best detection tool for 
men with serum PSA levels below 10 ng/mL and is rapidly 
approaching routine clinical practice.  
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Is early detection of prostate cancer justified? 
It is easy to get confused about the difference between screening, 
early detection and case finding. Screening means, a physician, 
does DRE and PSA in all men in the eligible age group in a 
community to detect early prostatic cancer. To add confusion, the 
word screening is used in different contexts like opportunistic 
screening (PSA in men consulting for unrelated disease), patient 
initiated screening and screening patients with risk factors (family 
history and black race). Early detection means, a physician, 
counsels every man in the eligible age group who comes to him to 
have a DRE and PSA, regardless of his symptoms. Case finding 
means, PSA and DRE is done in a select group of men, like those 
presenting with lower urinary tract symptoms. Men who have 
symptoms of prostatism do not have an increased risk of prostate 
cancer, and the specificity of PSA for prostate cancer is 
significantly reduced in this population of men. There is no 
controversy in requesting for PSA when there are symptoms and 
signs suggestive of prostate cancer. Public awareness of PSA is 
high in the Western world. Men routinely go to doctors and health 
fairs for PSA testing. Prominent stories in news magazines, 
television broadcasts, and radio advertisements emphasize the 
importance of screening in the western world. According to one 
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survey, 87% of family physicians and 98% of urologists reported 
using the test to detect early prostate cancer.35  
 
The general population harbors predominantly latent prostate 
tumors of doubtful clinical significance. Such tumors are indolent, 
they advance slowly and the individual generally succumbs to 
other diseases. Patients die with, rather than from, the disease. 
Autopsy studies of men over age 50 who lived their entire lives 
without prostatic symptoms demonstrate that about 30% harbor 
pathologic evidence of prostate cancer 36. Most of these tumors 
would go unrecognized if not investigated. There is some evidence 
that PSA detected tumors are of greater clinical significance than 
those detected on autopsy. 37  
 
Evidence that early detection improves outcomes is best obtained 
by randomized controlled trials. Bill-Axelson et al38 in a randomized 
control trial of 695 men assigned to radical prostatectomy and 
watchful waiting found that, there was statistically significant 
increase in cancer specific and overall survival in the radical 
prostatectomy group at the end of 10 years. More than 75 % of 
patients had T2 disease. Other observational studies have shown 
that survival among patients who receive no aggressive therapy 
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(watchful waiting) appears to differ little from outcomes with 
surgery or radiation. A widely cited study 39 of 223 conservatively 
treated Swedish men reported 10- and 15-year disease-specific 
survival rates of 85% and 81%, respectively. A study in 
Connecticut, also reported that conservative treatment resulted in 
survival rates resembling those of the general population.40 
Counselling all men over age 50 for early detection of prostate 
cancer would expose a large population to potential harm of 
unwarranted biopsy. Most persons who experience these adverse 
effects will not have cancer. These men will ultimately not benefit 
from early detection. They undergo an unpleasant experience of 
learning that their PSA test is abnormal, undergo a repeat PSA 
testing, ultrasound, or biopsy; and anxiously waiting to know 
whether they have cancer. No data quantify the morbidity of this 
experience or whether the upset for some patients is off set by the 
reassurance that others experience by receiving normal results. 
About 20% of screened population undergo needle biopsy,41 for 
which there is a low probability of local infection (0.35%), sepsis 
(0.6%), and bleeding (0.1%).42-44 
 
Treatments for prostate cancer carry a high risk of complications. 
Although urologists and radiation therapists believe that current 
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complication rates are lower, studies suggest that they remain high 
in the community. For example, a survey of Medicare patients who 
underwent prostatectomy reported that over 30% wore pads or 
clamps for incontinence, over 60% were impotent, and 15% 
required treatment for sexual dysfunction.45 Complications affecting 
sexual, urinary, and bowel function have a substantial impact on 
these aspects of quality of life.46 Although some patients are willing 
to risk these complications of treatment, others do not feel the risks 
are justified. In one study, 26% of patients (mean age 66 years) 
indicated a preference for expectant management over surgery, 
even if the latter would extend life by 10 years.47 
 
Individual Patient Counselling: 
Due to the lack of direct evidence about the benefits of early 
detection and the uncertainty about complication rates, it is 
impossible to make a direct quantitative comparison of benefits 
and harms. The ultimate judgment of whether benefits outweigh 
harms is subjective. The best option for the individual patient 
depends on personal preferences. A man’s fears, lifestyle and 
priorities dictate whether the balance of benefits and harms are 
favourable. Clinicians who make this decision for the patient 
presume, in effect, that they know the patient’s preferences or that 
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those preferences match their own. Neither presumption is 
justified; studies show that physicians are poor judges of their 
patient’s preferences. It is unethical for physicians to impose 
choices that reflect their own feelings about benefits and harms 
rather than those of the patient. Accordingly, instead of routinely 
performing or discouraging early detection of prostate cancer, 
most groups now recommend some form of shared decision 
making, in which clinicians (1) review with patients the facts about 
the benefits and harms of PSA testing, their likelihood, and the 
scientific uncertainty around the estimates; (2) help patients 
assess personal feelings and preferences about potential 
outcomes; and (3) help determine which choice is best. Although 
many patients ultimately turn to the physician for advice, a sizable 
minority appreciate the opportunity to make their own choice, as is 
their ethical right. A consensus on the need for this approach has 
emerged in recent guidelines. The American College of Physicians 
48 recommends that physicians describe the potential benefits and 
known harms of PSA testing, listen to the patient’s concerns, and 
then individualize the decision to screen. 
 Even organizations that promote prostate screening emphasize 
the need for shared decision making. The American Urological 
Association states that patient’s should be given information about 
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these tests and should be given the option to participate in 
screening. Yet shared decision making is uncommon in practice. 
Patients often undergo PSA screening without receiving 
information about the consequences and sometimes without even 
being told they received the test. In one study, over 50% of men 
who had undergone PSA screening two weeks earlier said they 
had not heard of the test and were unaware that they had received 
it.49 
In a 1995 survey, 55% of primary care physicians reported 
ordering the PSA test ‘often’ or ‘always’ in the periodic health 
examination; only 17% ‘rarely’ or ‘never’ ordered the test.50 A policy 
of uniformly performing or rejecting is inconsistent with shared 
decision making. For their part, physician’s face obstacles in 
practicing shared decision making.51 Busy clinicians lack the time 
for long discussions, and those with strong feelings about 
screening may consider such discussions unnecessary. Many 
clinicians are not sufficiently familiar with the data to present 
options and probability rates impartially. Others are unable to 
interpret patient’s preferences. For their part, patients may be 
overwhelmed by the data or by the prospect of making a decision 
that could cost them their life. Tools to deal with these problems 
are available. Brochures, audiotapes, videotapes, and interactive 
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videodisks for shared decision making present the options in a 
factual, balanced format.51 Clinicians can reconcile time demands 
by relying on other office staff to help present options and by 
inviting patients to review print and audiovisual materials at home. 
These tools do affect patient’s choices. Several studies have 
shown that giving patients information about benefits and harms 
and an opportunity to make their own choice decreases PSA 
testing by as much as 50%.52-53  
Early detection should only be discussed when there is a 
reasonable prospect of benefit. Experts agree that routine PSA 
test is inappropriate in young, normal-risk men under age 50; high-
risk men under age 40; or older or sick men with a life expectancy 
of less than 10 years. Despite this longstanding consensus, 
clinicians continue to perform PSA in older men. In one survey, 
65% of primary care physicians reported ‘almost always’ ordering 
a PSA test on men age 70-74; 53% reported doing so on men age 
80 and older.54 This practice is not limited to primary care. One 
survey found that the proportions of urologists recommending 
surgery or radiation for patients over age 70 were 48% and 74%, 
respectively.55  For men age 50-70 (or men age 40-70 who are 
African-American or who have a family history of prostate cancer) 
shared decision making is necessary to help patients decide 
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whether early detection is appropriate for them. Routinely 
encouraging   men to undergo PSA testing without discussion is 
unethical. Conversely, sceptical clinicians should avoid unilaterally 
discouraging patients who request PSA testing. Physician’s 
preferences for or against screening should be expressed and 
acted on when requested by the patient. It’s, the patient who will 
have to live with the consequences. 
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Different types of survey: 
Surveys can be divided into two broad categories: the 
questionnaire and the interview. Questionnaires are usually paper-
and-pencil instruments that the respondent completes. Interviews 
are completed by the interviewer based on the respondents 
answer. Interviews are a far more personal form of research than 
questionnaire. Questionnaire almost always are short closed-
ended, while interviews almost always are broad open-ended. But 
questionnaires can be open-ended (although they do tend to be 
shorter than in interviews) and there could be a series of closed-
ended questions in an interview. There are different types of 
questionnaires. 
Mailed questionnaire: 
There are many advantages to mailed questionnaire. They are 
relatively inexpensive to administer. The same instrument can be 
send to a wide number of people. They allow the respondent to fill 
it out at their own convenience. But there are some disadvantages 
as well. Response rates from mail surveys are often very low and 
mail questionnaires are not the best vehicles for detailed written 
responses. 
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Group questionnaire: 
A sample of respondents are brought together and asked to 
respond to a structured sequence of questions. Traditionally, 
questionnaires were administered in group settings for 
convenience. The researcher could give the questionnaire to those 
who were present and be fairly sure that there would be a high 
response rate. If the respondents were unclear about the meaning 
of a question they could ask for clarification. The same could be 
used in an individual setting instead of a group. Validated 
questionnaires will give better results. 
Household questionnaire: 
In this approach, a researcher goes to the respondent's home or 
business and hands the respondent the instrument. In some 
cases, the respondent is asked to mail it back or the interviewer 
returns to pick it up. This approach attempts to blend the 
advantages of the mail survey and the group administered 
questionnaire. Like the mail survey, the respondent can work on 
the instrument in private, when it's convenient. Like the group 
administered questionnaire, the interviewer makes personal 
contact with the respondent. The respondent can ask questions 
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about the study and get clarification on what is to be done. 
Generally, this would be expected to increase the percent of 
people who are willing to respond. 
 
Interviews 
 Personal interview: 
The interviewer works directly with the respondent. Unlike mail 
surveys, the interviewer has the opportunity to probe or ask follow-
up questions. Interviews can be very time consuming and they are 
resource intensive. The interviewer is considered a part of the 
measurement instrument and interviewers have to be well trained 
in how to respond to any contingency. 
Telephone interview: 
 Telephone interviews enable a researcher to gather information 
rapidly. Most of the major public opinion polls that are reported in 
the west were based on telephone interviews. Like personal 
interviews, they allow for some personal contact between the 
interviewer and the respondent. And, they allow the interviewer to 
ask follow-up questions. But they also have some major 
disadvantages. Many people don't have publicly-listed telephone 
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numbers. Some don't have telephones. People often don't like the 
intrusion of a call to their homes. And, telephone interviews have 
to be relatively short or people will feel imposed upon. 
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Materials & Methods 
The study was conducted in men between the age group of 50 and 
69 years. The participants in the study group should have 
completed their undergraduate degree and should be able to make 
an independent decision regarding health related issues. Target 
population included were; 1. patients and relatives attending the 
Urology clinic 2. patients with normal DRE, who had their PSA 
tested earlier with an intention to detect early cancer of the 
prostate by their physicians. All the participants were given a 
brochure on prostate cancer which included methods for its early 
detection. The content, was developed from the available 
literature, determined to be important in shared decision making. 
The brochure was written in a question and answer format 
(appendix 1).  The intervention stated the lifetime probability of 
developing and dying from prostate cancer, and the ability of the 
PSA test to detect early prostate cancer. It included the positive 
predictive value of PSA, and a brief description of the principal 
management options for early prostate cancer and their major 
complications. Those interested in filling up the questionnaire were 
enquired about their willingness to undergo tests for early 
detection of prostate cancer. The questionnaire was of the closed 
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end format (appendix 2), and if they could’nt give a definitive 
answer they were given the privilege to answer ‘I am not sure’. 
Participants were given the freedom to express their opinion in 
addition to the choices mentioned in the questionnaire and they 
can make more than one choice. Men who had their PSA tested 
elsewhere earlier, were enquired about their opinion as to whether 
they would have undergone the test had they known the facts 
about early detection of prostate cancer. All men with LUTS had 
DRE. Men with normal DRE were included in this survey. They 
were enquired regarding their willingness for PSA testing. It was 
decided to survey three different groups of men; the reasons for it 
are 1. Is there a difference in their willingness to undergo tests for 
early detection in those with and without symptoms? 2. Will an 
informed consent alter their decision to undergo tests for early 
detection?    Men in group 1 were asymptomatic. Men in group 2 
had LUTS and normal DRE. None of the patients in group 2 had 
PSA testing in the past. Men in group 3 had LUTS and normal 
DRE, but had PSA testing in the past.  There were thirty men in 
each group. 
 Validity of PSA and DRE was assessed by a retrospective 
analysis of men more than 40 years who had TRUS guided biopsy 
for abnormal DRE or PSA > 4ng./ml. or incidentally detected 
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lesions on TRUS during evaluation for hematospermia. Study 
period was between January 2002 and December 2005. Serum 
PSA was assayed using the Immulite 2000 kit. PSA more than 4 
ng./ml. was considered as abnormal for this analysis. Free PSA 
were done in all patients after March 2003. DRE was performed by 
an attending urologist or resident. For analytical purpose DRE was 
coded as normal or abnormal. A systematic TRUS guided sextant 
biopsy was performed by the radiologist with an 18 gauge biopsy 
needle using the biopty gun. Additional biopsy of  hypoechoic 
areas detected incidentally during TRUS was also biopsied.  
 
Statistical analysis of the frequency distribution of data was 
performed in the survey analysis using Statistical Package for the 
Social Sciences, version 11.0 (SPSS 11) software. The statistical 
analysis for assessment of validity of PSA and DRE was done 
using the same software. Positive predictive value was calculated 
from cross tabulation. Receiver operating characteristic curve was 
calculated for PSA.    
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Results 
Survey analysis: 
Mean age of the participants in group1, group 2 and group 3 were 
60, 59, 59 years respectively. Monthly income of men in three 
groups is shown in table 2. 
 
Table: 2 Monthly income 
Monthly 
income 
Group 1 (n-30) Group 2 (n-30) Group 3 (n-30) 
> 10,000 22 12 12 
5000-10,000 6 15 12 
< 5000 2 3 6 
 
 30% of men in group 1, 20% in groups 2 &3 were aware of the 
fact that PSA is done to detect prostate cancer. 40%, 80%, 73% of 
men were willing to undergo tests for early detection of prostate 
cancer in groups 1, 2 and 3 respectively. Participants willing for 
early detection in group 1 were willing for prostatic biopsy if any 
one of the test was abnormal. Those willing for early detection in 
groups 2 and 3 were willing for prostatic biopsy if PSA was 
abnormal. 10% of men in group 1 had their PSA tested earlier with 
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an intention to detect early cancer of the prostate after an informed 
consent by their physician. Of the 30 men in group 3, benefits and 
risks relating to PSA testing was discussed by their physician in 30 
% of patients. 70 % of the patients had their PSA tested without an 
informed consent. Of the 70 % who had a PSA without an 
informed consent 38% felt that they would not have undergone the 
test if the risks and benefits were explained to them prior to the 
test and 14 % were ‘not sure’ whether they would have undergone 
the test. 
The reason for willingness to undergo tests for early detection of 
prostate cancer is shown in table.3. Of those willing to undergo 
tests for early detection, 33%, 21% and 37% in groups 1, 2 and 3 
respectively had more than one reason for their willingness to 
undergo tests to detect early cancer of the prostate (table.3). 
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Table 3: Reason for willingness to undergo tests 
Reasons 
Group1 
n – 12/30 
Group2  
n – 24/30 
Group3 
n – 22/30 
I want to be proactive by doing these 
tests 
5 11 7 
This is the only way by which I can get 
rid of the disease 
3 6 6 
Combination of both 4 4 6 
 I am afraid of cancer so I would like to 
get it tested 
0 2 0 
I want to be proactive by doing these 
tests and I am afraid of cancer so I would 
like to get it tested. 
0 1 3 
  
Of those willing to undergo tests for early detection when enquired 
about their willingness for yearly PSA and DRE; 25%, 16% and 9% 
were not willing for it in groups 1, 2 and 3 respectively. 8% in group 
2 were ‘not sure’ about yearly PSA and DRE testing.  The reason 
for not willing to undergo tests for early detection is shown in 
Table.4. 
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Table 4: Reason for unwillingness to undergo tests 
Reasons Group 1 Group 2 Group 3 
Complications associated with 
treatment 
7 3 2 
Early detection is not a guarantee that 
cancer will be cured 
5 0 0 
Treatment may not be beneficial 
because many men will die from other 
causes 
3 0 0 
Early detection is not a guarantee that 
cancer will be cured and due to 
financial reasons 
2 0 0 
Early detection is not a guarantee that 
cancer will be cured and treatment 
may not be beneficial because many 
men will die from other causes 
1 3 3 
Early detection is not a guarantee that 
cancer will be cured and the 
complications associated with the 
treatment 
0 0 3 
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Of those not willing for early detection 17%, 50% and 75% in 
groups 1, 2 and 3 respectively had more than one reason for their 
unwillingness (table.4).  Financial constraint was only a part of the 
reason for their unwillingness in two patients. 
 
Validity of PSA and DRE: 
 In order to assess the validity of PSA and DRE, 192 men who had 
TRUS guided prostatic biopsies were analysed retrospectively. 
Mean age was 65 years (range 40- 93). 94 % had lower urinary 
tract symptoms. The distribution of digital rectal examination 
results and PSA values are shown in tables 5 and 6.   
 
Table 5: DRE results in 192 patients  
DRE No. (%) 
Normal 63 (32.8) 
Suspicious for carcinoma 129 (67.2) 
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Table 6: PSA results in 192 patients 
PSA value in ng./ml. No. (%) 
<4 22 
4.1-10 51 
10.1-20 47 
20.1-50 33 
>50.1 39 
 
 
78% of patients had PSA more than 4 ng./ml., 67% had abnormal 
DRE and both tests were abnormal in 57%. Of the patients with 
elevated PSA 47% had malignancy on biopsy. Positive predictive 
value of PSA was 47%. Of the patients with abnormal DRE, 57% 
of patients had malignancy on biopsy. Positive predictive value of 
DRE was 57% Table 7 shows the percentage of men with 
malignancy with different PSA range. 
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Table 7: PSA range and biopsy result 
PSA in ng./ml. (n) Malignancy on biopsy (%)  
< 4 (22) 1 (4.7) 
4-10 (51) 4 (7.8) 
10.1-20 (47) 16 (34) 
20.1-50 (33) 23 (64.6) 
>50(39) 37 (94.8) 
Total 81 
 
 8% of patients with PSA between 4 and 10 had malignancy.  Free 
total ratio was performed in all patients after 2003. 84% with PSA 
between 4 and 10ng./ml. had free total ratio. In those who had 
malignancy in the PSA range between 4 and 10 ng./ml. 75% had 
free total ratio of less than 18%. An elevated PSA level > 50 
ng./ml. was strongly predictive of carcinoma. Table 8 shows the 
percentage of men with malignancy for normal and abnormal 
combination of PSA and DRE. 
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Table 8: Percentage of men with malignancy with 1 or 2 positive 
tests and 1 or 2 negative tests 
PSA in 
ng./ml. 
DRE               Biopsy 
Benign(%)  Malignant (%)
Total 
> 4 Normal 53(88.3%) 7(11.7%) 60 
Abnormal 37(33.6%) 73(66.4%) 110 
< 4 Normal 3(100%) 0 3 
Abnormal 18(94.7%) 1(5.3%) 19 
 
 If the PSA was normal and DRE was abnormal 5% had 
malignancy. If the PSA was >4 ng./ml. and DRE was normal 12% 
had malignancy. If both the tests were abnormal 66% had 
malignancy.  PSA influenced the positive biopsy rate in those with 
abnormal DRE (table 9). It is important to note that the positive 
predictive value of DRE increased with increasing PSA.  
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Table. 9 Malignancy in men with normal or abnormal DRE and 
abnormal PSA 
PSA in 
ng./ml. 
DRE 
              Biopsy 
Benign(%)  Malignant (%)
Total 
4.1 - 10 
Normal 31(100%) 0 31 
Abnormal 16(80%) 4(20%) 20 
10.1-20 
Normal 15(88%) 2(12%) 17 
Abnormal 16(53%) 14(47%) 30 
20.1-50 
Normal 6(75%) 2(25%) 8 
Abnormal 4(16%) 21(84%) 25 
>50 
Normal 1(25%) 3(75%) 4 
Abnormal 1(3%) 34(97%) 35 
 
 
 
ROC for PSA is shown in figure 1. The area under the curve for 
PSA is 0.897. ROC processing is shown in appendix 3. 
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Fig. 1 : Receiver operating characteristic curve for PSA.  
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Discussion 
Survey analysis 
Many clinicians believe intuitively in the benefit of early detection. 
Whether the balance of benefits and harms favors or impugns 
early detection, and whether it is ethical to withhold early detection 
until definitive proof becomes available, are ultimately matters of 
opinion. Proponents believe that the benefits outweigh the harms 
and that early detection for a fatal disease is not unethical. 
Skeptics believe that the harms may outweigh the benefits and 
that early detection without first proving safety is unethical. 
Patients should be asked to assume an increasing level of 
responsibility in early detection of prostate cancer knowing the fact 
that there is no direct evidence in favor of it. This shared decision 
making, which defines the physician and patient as co-participants 
in a process of managing personal health and well being, has 
largely supplanted the more traditional model in which the 
physician assumes most of the responsibility for choosing a health 
care strategy that is in the best interests of the patient. There are a 
number of obstacles to achieving the ideals of shared decision 
making. Firstly, patients vary in terms of familiarity with medical 
terminology and beliefs about health and illness. Secondly, 
patients generally would like to receive as much information as 
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possible about options available to them. However the extent to 
which patients wish to be involved in treatment decisions is 
variable. Many patients will still view physicians as experts who 
can give them the right decision that should be made to resolve 
uncertainties. The other problem is how information should be 
presented and what should be presented. The information 
presented to the participants in this survey is similar to the 
information provided by other investigators.56,57,58 Physicians, 
themselves, differ in how effectively they convey complex medical 
information in a manner that is easily understood and level of 
commitment in facilitating shared decision making. If the goal is to 
maintain patient autonomy, then it is crucial that information be 
presented in such a way that does not serve to influence patient 
decision making. The amount of time that is available for 
physicians to devote for discussions about screening may further 
constrain the extent to which this goal of shared decision making 
could be achieved.  Awareness about PSA is between 20 & 30% in 
this survey. In the western world awareness varies between 65% 
and 85% depending on the race and educational level.59,60  This  
difference is probably due to the lack of advertisements in 
television, radiobroadcast and articles in news magazine. 
Asymptomatic men were more reluctant for early detection 
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whereas those with LUTS were willing for early detection. 40% of 
asymptomatic men (group 1), 80% in group 2 and 73% in group 3 
were willing for early detection. This is probably due to the belief 
that prostate cancer is unlikely to exist in the absence of 
symptoms. Wanefried et al60 in their analysis on knowledge, beliefs 
on prostate cancer screening, 46% of blacks and 30% of whites 
did not agree with the statement that a man can have prostate 
cancer without symptoms. Research is increasing on the 
development of aids that may be used to accomplish these goals 
in relation to prostate cancer early detection and treatment. 
Studies find that educating men about benefits and limitations of 
the PSA test reduces rather than promotes requests for the test. 
Volk et al61 reported on a study concerning the knowledge of 
prostate cancer in men who presented at a university based family 
medicine clinic. Men were randomly assigned either to a control 
group or intervention group. Men in the intervention group were 
shown a 20 minute videotape that presented information on pros 
and cons of PSA testing. It was determined that men in the 
intervention group provided more accurate responses to survey 
items that concerned early prostate cancer mortality rates, 
performance characteristics of PSA and treatment related 
complications. In yet another study by Wolf et al53 using scripted 
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information on prostate cancer screening, found that patients who 
received intervention were significantly less interested in 
undergoing PSA screening than controls. Various studies 52,58 
utilize booklets and videotapes to educate patients on shared 
decision making for screening and treatment of early prostate 
cancer. These studies show that those exposed to educational 
tools had increased interest in playing an active role in decision 
making. Wilt et al58 in their randomized trial of a mailed pamphlet 
about the pros and cons of PSA testing prior to consultation, found 
that there was no difference in the opinion on annual PSA 
screening in the intervention group and control group. When asked 
about a hypothetical question as to ‘what treatment they would 
choose if they ever received a diagnosis of prostate cancer’, men 
in the intervention group were more likely to choose watchful 
waiting. PSA was tested in 70% of group 3 patients without an 
informed consent. Nearly 38 % of them would not have undergone 
the test if an informed consent has been obtained prior to the test. 
In a similar study by Federman et al62 30% were unaware that the 
physicians had ordered a PSA test. Of the patients aware of 
receiving the test only 47% recalled having a discussion with their 
primary care provider about the risks and benefits of screening. 
PSA testing without information or inclusion in routine 
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examinations such as master health checkup is unacceptable 
ethically.        
Validity of PSA and DRE: 
The cancer detection rate in this study cannot be compared with 
cross-sectional or longitudinal studies as majority of patients had 
PSA for abnormal DRE and subsequently a TRUS guided biopsy 
was performed. Positive predictive value of PSA > 4 ng./ml. was 
12%, if the DRE was normal, in this study. Hammerer et al63 found 
that 12% of patients had malignancy when the PSA was > 4 
ng./ml. and with normal DRE. They also found that the positive 
predictive value of DRE increased with increasing PSA. The 
chance of cancer on biopsy when PSA was more than 4 ng./ml. 
and with normal DRE in other series varied from 24-32%.64,65,66 
Cancer detection rate in this study was 8% when the PSA was 
between 4 and 10 ng./ml. When the DRE was negative none of 
them had positive biopsy and when the DRE was positive 20% had 
malignancy. Cooner et al65found that the positive predictive value 
of PSA between 4 and 10 ng./ml., when the DRE was normal was 
20%, and 45% if the DRE is positive. Brawer et al67 in their series 
found that 54 % and 60% had malignancy with a  PSA cut off of > 
4 and >10 ng./ml. respectively in men with abnormal DRE. In this 
study we found that 66% and 77% had malignancy with a PSA cut 
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off of > 4 and > 10 ng./ml. respectively in men with abnormal DRE. 
The chance of cancer in men with PSA > 4 ng./ml. and abnormal 
DRE in other series varied from 42-72 %.63,64,65,66,68,69    In this study 
the cancer detection rate was negligible in men with PSA < 10 
ng./ml., especially in those with normal DRE. This contradicts the 
report by Thompson et al70; they found that in men with normal 
DRE and PSA < 4 ng./ml. cancer detection rate was 15%. This 
might be due to the decreased incidence of  prostatic malignancy 
in Asian men.  Prostate cancer incidence in many high-risk 
countries is likely to be affected by aggressive screening in their 
population, while the lack of screening, the lower quality of cancer 
diagnosis may be the cause for under reporting in Asian countries. 
However in a study conducted in Taiwan, the positive biopsy rate 
for patients with serum PSA levels of 4.1–20.0 ng/mL was 
14.6%.71 In Korea, among the 240 patients whose PSA levels were 
4–20 ng/mL, only 38 were diagnosed with prostate cancer by 
prostate biopsies, which corresponded to a 16% incidence.72 Even 
if the possibility of missing a few instances of cancer was taken 
into account, these incidences are substantially lower than the > 
25% incidence among patients with comparable PSA. The positive 
predictive value of DRE is apparently higher than the value for 
PSA. This is partly due to selection bias and also by the fact that 
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38% of patients had PSA < 10 ng./ml. and the cancer detection 
rate in them was 6.8%. If the PSA cut off is increased to >10 
ng./ml. the positive predictive value of PSA increased from 47 % to 
64%. From the receiver operating characteristic curve we found 
that for a sensitivity of 80% and specificity of 80% the PSA cut-off 
value was 14.3 ng./ml.  
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Conclusion  
Based on this survey, providing educated men with balanced 
information gives them an opportunity to make decisions 
commensurate with their own values and will perhaps make them 
to be better equipped to deal with the consequences of  early 
detection. Though informed consent is mandatory prior to PSA 
testing, informed consent was not obtained in majority of group 3 
patients prior to the test. A brochure is a low cost method that can 
improve men’s knowledge about risks and benefits of early 
detection and treatment of prostate cancer. The information 
provided in the brochure can be used to counsel men who 
specifically ask their physician for a PSA test.  DRE and PSA are 
not specific tools to detect prostatic malignancy. It seems that men 
with PSA between 4 and 10 ng./ml. are more likely to harbor 
benign disease unlike men in the western world.  
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Limitations 
Survey analysis 
Validated information regarding what patients should know prior to 
PSA testing is not available in the literature. The information 
contained in the brochure is similar to the information provided by 
other investigators but it was tailored according to the needs of our 
patients. The questionnaire provided to men in the western world 
cannot be used in our setting, because of the increased 
awareness about screening for prostate cancer among men in the 
western world. Validated questionnaire to suit our patients is not 
available, so this questionnaire was designed according to the 
needs of our patients. Patient interest in PSA screening was used 
as a surrogate marker for actual screening behavior. We cannot 
predict with certainty how patient interests would translate into his 
decision to have the test done, though it seems likely that those 
who expressed a desire would choose to be tested. This survey 
was done in a select group of educated men, so it cannot be 
generalized to the community setting.   
Validity of PSA and DRE 
The patients do not represent a screening population but a 
population comprised primarily of those who had an indication for 
biopsy. DRE was performed by different individuals so there may 
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not be uniformity in the findings. It is a well known fact that DRE 
has significant intra and inter-observer variability. Majority of men 
with elevated PSA and negative biopsy did not have a repeat 
biopsy. A laterally directed, 12 core or saturation biopsies could 
have detected malignancy in few men. Well conducted cross 
sectional/longitudinal studies are required to assess the positive 
predictive value of PSA and DRE. An ideal study would involve 
screening a population with PSA, DRE and systematic biopsy 
followed by prostatectomy. Histological analysis of the entire 
prostate should be done to have a standard against which 
comparison can be done. This is hypothetical and could probably 
never be conducted. 
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           Appendix -1 
 
 
Dear participant, 
The department of Urology is interested in assessing the 
willingness of the people in the community regarding early 
detection of prostatic cancer.   There are only few cancers that can 
be detected at an early stage and prostate cancer is one of them. 
One of the early indicators of the disease is elevated PSA (blood 
test).  Another method of diagnosis is to do an examination of the 
prostate by passing a finger into the rectum.   
 
 This study specifically aims to assess the willingness of the 
participants in the age group of 50 – 69 years to undergo the 
above tests. If any one of the test is found to be abnormal, biopsy 
test of the prostate should be done to exclude cancer.  Those 
willing to undergo these tests need to understand the merits and 
demerits of these tests. 
 
Some Facts about the prostate gland and cancer of the prostate 
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Where is the prostate gland situated? 
Prostate gland is situated just below the urinary Bladder.  
 
What is the function of the gland? 
It is a secondary sex gland and plays a role in  the formation of 
semen. It also produces  an enzyme called PSA. 
 
What conditions produces an elevation  in PSA? 
Infection, benign (noncancerous) tumors and cancer. 
 
At what age does cancer begins to occur in this gland? 
Usually cancer occurs after the age of fifty. This is also the age 
where noncancerous enlargement of the prostate occurs. Non 
cancerous enlargement is much more common than cancerous 
enlargement. 
 
What are the symptoms of cancer? 
In the early stage there may not be any symptoms. Urinary 
symptoms like reduced speed, straining to pass urine and frequent 
urination are most commonly caused by non-cancerous 
enlargement of the prostate. Cancer of the prostate in late stages 
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can produce obstruction to urinary passage resulting in the above 
symptoms and also symptoms due to spread of the disease. 
 
What is the risk of getting cancer during a person’s lifetime? 
Western data states that out of hundred men, thirteen men are at 
risk of developing cancer during their lifetime. 
 
How many of them will die of prostatic cancer? 
Two to three men will die of prostatic cancer; the rest of the men 
will have the cancer but will die of other diseases, as this is a slow 
growing cancer. 
 
How can this cancer be detected at an early stage? 
Prostate cancer is detected by testing the blood for PSA; the 
detection rate of cancer is further increased by a simple testing of 
the prostate gland using the finger through the rectum shown in 
figure below. 
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Beyond which level is PSA considered to be abnormal? 
Value greater than 4 ng./ml. is generally considered as abnormal. 
Chance of  cancer increases with increasing PSA. 
  
If the tests are abnormal does it mean that there is cancer? 
The answer is no. PSA might be elevated in various conditions like 
infection, benign (non cancerous) enlargement of the prostate etc. 
Of the patients with PSA level between 4-10 ng/ml only 25% will 
have cancer. If the finger testing is abnormal  less than 50 % will 
have cancer. 
      
Will PSA be elevated in all men with cancer of the prostate? 
The answer is no. PSA might be in the normal range in 25% of 
men with cancer of the prostate. 
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What should be done if any one of them is abnormal? 
If the PSA is elevated or if the finger test is abnormal then the 
person should undergo biopsy of the prostate to rule out cancer. 
 
Is it advisable to do any one of these tests? 
No, the recommendation is to do both the tests as the detection 
rate of cancer increases if both the tests are combined together. 
 
How is prostatic biopsy done? 
Biopsy is done through the rectum (motion passage) under 
ultrasound guidance. 
 
Does biopsy produce pain or any other complication? 
There might be a mild discomfort during the procedure. The 
complications associated with the biopsy are very minimal if 
adequate precautions are taken. The complication rate is 
approximately around 0.5%, which includes fever, hematuria and 
urinary retention. If the preliminary tests reveal that the bladder 
emptying is inadequate, prior to biopsy it would be necessary to 
drain the urine by catheter.  
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Is one time testing with PSA & finger testing of the prostate 
sufficient to detect cancer? 
The answer is no. Periodic testing should be done at least once in 
a year. One time testing may not be sufficient to detect early 
cancer of the prostate, even though it may be negative during the 
earlier testing. 
 
What should be done if the PSA is elevated but the biopsy is 
negative? 
The patient should be followed up with repeat PSA testing at 6 
months and repeat biopsy later if necessary. 
 
What are the treatment options for the early stage cancer? 
1. Regular followup with PSA testing and further treatment if the 
PSA levels increase rapidly 
2. Surgery  
3. Radiation. 
The treating doctor may recommend any one of the treatment 
options. 
Each method of treatment is associated with its own limitation and 
complications. 
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What is the problem with regular follow-up with PSA testing? 
It produces anxiety in some patient, as he knows that he has 
cancer and nothing is being done. 
 
What are the complications of surgery? 
Decreased penile erections (70%), urinary leak (2-5%) and the risk 
associated with surgery and anesthesia. 
 
What are the complications of radiation? 
There may be some urinary and rectal symptoms like increased 
frequency of urination and defecation, pain in the urinary and 
motion passage. These symptoms gradually subside over a period 
of 6-8 weeks. The risk of severe rectal and urinary complication is 
about 3% each. 
 
Has it been proved beyond doubt that early detection and 
treatment reduces the risk of death from cancer? 
The answer is no. Various studies are being done to know whether 
early detection and treatment decreases the risk of death from 
prostate cancer, the results of the studies are awaited. 
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Is prostatic cancer a common disease in India? 
The answer is yes. It is the fifth most common cancer among men 
in Chennai, Bangalore and Bombay. In America prostate cancer is 
the second most common cancer in men. 
 
What will be the approximate cost for testing? 
The cost of the PSA test is Rs 500.There is no additional charge 
for finger testing of the prostate, as it is part of clinical examination. 
The cost for performing biopsy if the above tests are abnormal is 
Rs 1475.  
 
What will be the additional duration of stay? 
PSA and finger testing doesn’t require additional duration of stay, if 
biopsy is required additional duration of stay will be by 1 week.  
 Why should it be done (PSA testing and finger testing) 
¾ Advanced prostate cancer is not curable. 
¾ In the absence of early testing, only a few men will be 
diagnosed with early curable prostate cancer. 
¾ Improves early detection of prostate cancer 
¾ Early detection is the best way to minimize the risk of death 
from prostate cancer  
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Why it should not be done (PSA testing and finger testing) 
¾ No study has been done to prove that early detection reduces 
the death rate from prostatic cancer 
¾ Many men will die from other causes before suffering from 
advanced disease 
¾ Current treatment in the form of operation and radiation may 
cause complication in some men 
¾ Improving early detection is not a guarantee that cancer deaths 
will be prevented 
¾ PSA will be elevated in only 75 % of men with prostate cancer 
 
I hereby consent to participate further in the study and I am willing 
to answer the questionnaire in the subsequent part of the study. 
         
 
           
      Signature of the participant 
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    Appendix - 2 
 
     Proforma 
 
1. Name:      2.Age: 
 
3. Level of education:  (Tick any one of the choices) 
 1. Below 5th class 
 2. Between 6th and 12th class 
 3. Graduate 
 
4. Profession:  (Mention your profession) 
    1. 
 
5. Monthly income: (Tick any one of the choices) 
   
 1. <5000Rs /month 
 2. 5000-10,000/month 
 3. >10,000/month 
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6. Purpose of visit to CMC: (Tick any one of the choices) 
 1. As a patient to Urology department 
 2. As a relative of a patient 
 
7. Do you have any urinary problem? (Tick any one of the choices) 
   1. Yes    2. No 
   
8. If yes: Please fill the symptom score in the last page (IPSS 
score)    
 
9. Do you know that there is a blood test, which can detect early 
cancer of the prostate before participating in the study? (Tick any 
one of the choices) 
    1. Yes    2. No            3. I am not sure 
 
10. Are you willing to undergo the blood test and finger testing of 
the prostate through the rectum for early detection of prostate 
cancer? Both the tests should be done for early detection of 
cancer?  
(Tick any one of the choices) 
    1. Yes    2. No            3.I am not sure 
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11. If the blood test shows elevated PSA, or the finger test is 
abnormal you need to consult an urologist and you will be advised 
to undergo biopsy of the prostate; are you willing for this? (Tick 
any one of the choices)   
 1.Yes   2. No  3. Iam not sure 
 
12.Has PSA testing been done earlier? (Tick any one of the 
choices) 
    1.Yes     2.No  
 
13.If PSA has been tested earlier have you been explained about 
the merits and demerits of testing (applicable only if you tick yes to 
question no 12) 
 
    1. Yes   2.No 
 
14.If the merits and demerits have been explained to you at the 
time of testing what would have been your response (applicable 
only if you tick yes to question no 12) 
 1. I would have undergone the test 
 2. I wouldn’t have undergone the test 
 3. I am not sure. 
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15. If you want to undergo early detection of prostate cancer what 
is the reason for it? 
(You can tick one or more reasons, if you tick the fourth choice 
kindly mention the reason) 
 1. I want to be proactive by doing these 
tests  
 2. I am afraid of cancer, so I would like to 
get it tested  
 3. This is the only way by which I can get 
rid of the disease 
 4. Any other reason (if so please mention 
below) 
 
16. Are you willing for yearly PSA testing and finger testing (Tick 
any one of the choices) 
  
 1.Yes   2.No   3. I am not sure   
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17. If you don’t want it tested what is the reason? 
(You can tick one or more choices, if you choose the sixth choice 
kindly mention the reason.) 
 1. Early detection is not a guarantee that 
cancer will be cured 
 2. Complications associated with the 
treatment 
 3. Treatment may not be beneficial 
because many men will die from other 
causes before suffering from advanced 
cancer 
 4. Financial problems 
 5. Fear of being diagnosed to have cancer 
 6. Any other reason (if so please mention 
below)      
         
THANK YOU FOR TAKING THE TIME TO ANSWER THIS 
QUESTIONNAIRE. IF YOU HAVE ANY FURTHER QUESTIONS 
PLEASE FEEL FREE TO ASK. 
 
 
                                            Signature of the participant 
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Appendix 3 
 
roc psa by biop_r (1)/ plot = curve(reference) / print = se 
coordinates. 
 
Case Processing Summary  
BIOP_R Valid N (listwise) 
Positive(a) 81
Negative 111
Larger values of the test result variable(s) indicate stronger 
evidence for a positive actual state.  
a The positive actual state is Malignant.  
 
Area Under the Curve  
Test Result Variable(s): PSA  
Area 
Std. 
Error(a) 
Asymptotic 
Sig.(b) 
Asymptotic 95% 
Confidence Interval 
Lower Bound Upper Bound
.897 .023 .000 .851 .942
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The test result variable(s): PSA has at least one tie between the 
positive actual state group and the negative actual state group. 
Statistics may be biased.  
a Under the nonparametric assumption  
b Null hypothesis: true area = 0.5  
 
Coordinates of the Curve  
Test Result Variable(s): PSA  
Positive if Greater Than or 
Equal To(a) 
Sensitivity 1 – Specificity 
-.950 1.000 1.000
.225 1.000 .991
.410 1.000 .982
.510 1.000 .973
.625 1.000 .964
.755 1.000 .955
.930 1.000 .946
1.080 1.000 .937
1.280 1.000 .928
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1.450 .988 .928
1.530 .988 .919
1.780 .988 .910
2.080 .988 .901
2.255 .988 .892
2.475 .988 .883
2.700 .988 .865
2.950 .988 .856
3.300 .988 .847
3.600 .988 .838
3.800 .988 .820
4.050 .988 .811
4.250 .988 .793
4.550 .988 .784
4.900 .988 .775
5.150 .988 .766
5.350 .988 .757
5.450 .975 .748
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5.600 .975 .721
5.800 .975 .712
6.045 .975 .703
6.205 .975 .694
6.260 .975 .685
6.400 .975 .667
6.550 .975 .658
6.650 .963 .640
6.800 .963 .631
6.950 .963 .622
7.050 .963 .613
7.190 .963 .595
7.290 .963 .586
7.305 .963 .577
7.330 .963 .568
7.475 .963 .559
7.700 .963 .532
7.850 .963 .514
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7.950 .963 .505
8.300 .963 .477
8.650 .963 .468
8.750 .963 .459
8.900 .963 .450
9.150 .951 .450
9.330 .951 .441
9.430 .951 .432
9.600 .951 .423
9.750 .951 .396
9.850 .938 .396
10.000 .938 .387
10.150 .938 .378
10.250 .938 .369
10.400 .938 .360
10.550 .938 .351
10.700 .926 .351
10.900 .926 .342
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11.150 .889 .342
11.350 .877 .342
11.600 .864 .315
11.900 .852 .306
12.100 .852 .261
12.450 .852 .252
12.900 .852 .243
13.200 .852 .234
13.500 .852 .225
13.850 .852 .216
14.300 .827 .216
14.800 .827 .207
15.100 .815 .207
15.400 .802 .207
16.300 .802 .198
17.250 .790 .198
17.550 .778 .198
17.800 .778 .189
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18.250 .778 .162
18.600 .778 .153
18.850 .753 .153
19.500 .753 .135
20.500 .741 .108
21.450 .716 .099
21.950 .716 .090
22.800 .704 .081
23.700 .704 .072
23.900 .691 .072
24.200 .679 .063
25.050 .667 .063
25.850 .654 .063
26.850 .654 .054
27.850 .654 .045
28.500 .654 .036
29.150 .630 .036
29.450 .617 .036
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30.050 .605 .036
30.650 .593 .036
30.900 .580 .036
31.350 .580 .027
32.750 .556 .027
35.100 .543 .027
38.550 .531 .027
41.350 .519 .027
42.400 .506 .027
44.400 .494 .027
46.350 .481 .018
47.300 .469 .018
49.950 .457 .018
54.000 .432 .018
58.000 .420 .018
61.500 .420 .009
63.450 .407 .009
66.450 .395 .009
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70.000 .383 .009
71.250 .370 .009
75.750 .358 .009
83.800 .346 .009
87.800 .333 .009
90.000 .321 .009
95.500 .309 .000
100.500 .296 .000
110.500 .284 .000
134.500 .272 .000
175.000 .049 .000
201.000 .000 .000
The test result variable(s): PSA has at least one tie between the 
positive actual state group and the negative actual state group.  
a The smallest cutoff value is the minimum observed test value 
minus 1, and the largest cutoff value is the maximum observed 
test value plus 1. All the other cutoff values are the averages of 
two consecutive ordered observed test values.  
 
Master chart - 1 
 
 
 
Age 
 
educat
ion 
Monthly 
income 
LUT
S 
Awaren
ess on 
PSA 
Willingn
ess for 
PSA 
&DRE 
Willingn
ess for 
biopsy 
PSA 
tested 
earlier
if so 
consent 
before 
PSA 
If consent has 
been 
obtained 
before PSA, 
you would 
have agreed 
or refused 
Reason for 
willingness
reason 
for 
unwillin
gness 
Willing for 
yearly PSA 
&DRE 
64 3 3 2 2 2 2 2 0 0 0 2 2 
65 3 3 2 1 1 1 1 1 1 1,3 0 1 
64 3 3 2 2 2 2 2 0 0 0 2 2 
64 3 2 2 2 1 1 2 0 0 1 0 2 
58 3 3 2 1 2 2 2 0 0 0 1,4 2 
54 3 1 2 1 1 1 2 0 0 1,3 0 1 
68 3 2 2 2 1 1 2 0 0 3 0 1 
67 3 3 2 2 2 2 2 0 0 0 1 2 
58 3 3 2 2 2 2 2 0 0 0 3 2 
52 3 3 2 2 2 2 2 0 0 0 2 2 
58 3 2 2 2 2 2 2 0 0 0 2 2 
62 3 3 2 2 1 1 2 0 0 3 0 1 
68 3 3 2 2 2 2 2 0 0 0 2 2 
58 3 2 2 1 1 1 1 1 1 1,3 0 1 
63 3 3 2 2 2 2 2 0 0 0 1 2 
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64 3 1 2 2 2 2 2 0 0 0 3 2 
55 3 3 2 1 2 2 2 0 0 0 1,3 2 
57 3 3 2 1 1 1 2 0 0 1 0 1 
68 3 3 2 2 2 2 2 0 0 0 1 2 
51 3 2 2 2 2 2 2 0 0 0 3 2 
59 3 3 2 1 1 1 1 1 1 1 0 1 
61 3 3 2 2 2 2 2 0 0 0 2 2 
53 3 2 2 2 1 1 2 0 0 3 0 1 
66 3 3 2 1 1 1 2 0 0 1 0 1 
63 3 3 2 2 2 2 2 0 0 0 2 2 
52 3 3 2 2 2 2 2 0 0 0 1 2 
67 3 3 2 1 2 2 2 0 0 0 1,4 2 
62 3 3 2 2 1 1 2 0 0 1,3 0 2 
55 3 3 2 2 2 2 2 0 0 0 1 2 
64 3 3 2 2 1 1 2 0 0 1 0 2 
58 3 3 1 2 1 1 2 0 0 1,2 0 1 
51 3 3 1 2 2 2 2 0 0 0 2 2 
64 3 1 1 1 1 1 2 0 0 1,3 0 1 
53 3 3 1 1 1 1 2 0 0 1 0 2 
62 3 2 1 2 1 1 2 0 0 3 0 1 
65 3 2 1 2 1 1 2 0 0 3 0 1 
65 3 2 1 2 1 1 2 0 0 1 0 3 
65 3 2 1 2 1 1 2 0 0 1 0 1 
56 3 3 1 2 1 1 2 0 0 1,3 0 1 
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60 3 2 1 2 2 2 2 0 0 0 1,3 2 
52 3 2 1 2 1 1 2 0 0 3 0 1 
65 3 2 1 1 1 1 2 0 0 1 0 1 
63 3 1 1 2 1 1 2 0 0 1,3 0 1 
61 3 3 1 2 1 1 2 0 0 3 0 1 
59 3 2 1 2 2 2 2 0 0 0 1,3 2 
58 3 1 1 2 1 1 2 0 0 1 0 2 
50 3 2 1 2 2 2 2 0 0 0 1,3 2 
53 3 2 1 2 1 1 2 0 0 1 0 1 
68 3 3 1 2 2 2 2 0 0 0 2 2 
52 3 2 1 2 1 1 2 0 0 1 0 1 
59 3 3 1 2 2 2 2 0 0 0 2 2 
68 3 2 1 2 1 1 2 0 0 2 0 1 
55 3 3 1 1 1 1 2 0 0 1 0 1 
61 3 2 1 1 1 1 2 0 0 1 0 3 
66 3 3 1 2 1 1 2 0 0 2 0 1 
54 3 2 1 2 1 1 2 0 0 1 0 1 
57 3 3 1 2 1 1 2 0 0 3 0 1 
63 3 3 1 2 1 1 2 0 0 1 0 3 
52 3 3 1 1 1 1 2 0 0 1,3 0 3 
54 3 2 1 2 1 1 2 0 0 3 0 1 
53 3 2 1 2 1 1 1 1 1 1,3 0 1 
54 3 2 1 2 1 1 1 2 3 3 0 1 
60 3 1 1 2 1 1 1 2 1 3 0 1 
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54 3 3 1 2 2 2 1 2 2 0 1,3 2 
58 3 3 1 2 1 1 1 1 1 1 0 1 
64 3 2 1 2 1 1 1 2 1 1 0 1 
65 3 1 1 2 2 2 1 2 2 0 1,2 2 
62 3 3 1 1 1 1 1 2 1 1,2 0 2 
60 3 3 1 1 1 1 1 1 1 1,3 0 1 
63 3 2 1 2 2 2 1 2 2 0 2 2 
60 3 2 1 2 1 1 1 2 3 3 0 1 
66 3 1 1 2 2 2 1 2 2 0 1,3 2 
64 3 1 1 2 1 1 1 2 3 3 0 2 
62 3 2 1 2 2 2 1 2 2 0 1,3 2 
54 3 2 1 2 1 1 1 1 1 1,3 0 1 
60 3 3 1 1 1 1 1 2 1 1,2 0 1 
58 3 2 1 2 1 1 1 1 1 1,3 0 1 
52 3 3 1 2 1 1 1 1 1 1 0 1 
61 3 3 1 2 2 2 1 2 2 0 1,2 2 
53 3 2 1 2 1 1 1 2 1 1 0 1 
50 3 2 1 2 1 1 1 2 1 3 0 1 
65 3 3 1 2 1 1 1 2 1 1 0 1 
63 3 2 1 2 2 2 1 2 2 0 1,2 2 
57 3 3 1 1 1 1 1 1 1 1,3 0 1 
57 3 1 1 2 2 2 1 2 2 0 2 2 
59 3 3 1 2 1 1 1 2 1 3 0 1 
62 3 3 1 1 1 1 1 2 1 1,2 0 1 
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62 3 1 1 2 1 1 1 2 1 1 0 1 
55 3 3 1 1 1 1 1 1 1 1,3 0 1 
54 3 2 1 2 1 1 1 1 1 1 0 1 
 
 
 
 
 
1. Education (Below 5th class-1, class 6 to 12 - 2, Graduate - 3) 
 
2. Monthly income (< 5000 - 1, 5000 to 10000 - 2, >10000 - 3) 
 
3. LUTS (Yes-1, No-2) 
 
4. Awareness about PSA (Yes-1, No-2) 
 
5. Willingness for PSA and DRE (Yes-1, N0-2) 
 
6. Willingness for biopsy (Yes-1, N0- 2) 
 
7. Past history of PSA testing (Yes-1, No-2) 
 
8. Informed consent obtained before PSA (Yes-1, No-2, not applicable - 0) 
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9. If informed consent has been obtained -you would have agreed for PSA testing (Yes -1, No- 2, not sure - 3, not applicable 
- 0) 
 
10. If willing for early detection what is the reason (I want to be proactive by doing these tests- 1; This is the only way by 
which I can get rid of the disease – 3; Combination of both -1, 3; I am afraid of cancer so I would like to get it tested -2; I 
want to be proactive by doing these tests and I am afraid of cancer so I would like to get it tested -1, 2; not applicable - 0) 
 
11. If not willing for early detection what is the reason ( Early detection is not a guarantee that cancer will be cured -1; 
Complications associated with treatment – 2; Treatment may not be beneficial because many men will die from other causes 
– 3; Early detection is not a guarantee that cancer will be cured and due to financial reasons- 1,4; Early detection is not a 
guarantee that cancer will be cured and treatment may not be beneficial because many men will die from other causes 1,3; 
Early detection is not a guarantee that cancer will be cured and the complications associated with the treatment-1,2;  not 
applicable -0.) 
 
12. Willing for early PSA and DRE (Yes-1, No-2) 
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Marter chart - 2 
 
Hospital 
no Age LUTS PSA
Free 
PSA DRE
Minimum 
no of 
cores 
Biopsy 
report 
228884C 48 1 5.5 NA 2 6 1 
141426B 65 1 12 NA 1 6 1 
235493C 79 1 0.42 NA 2 6 1 
234771C 67 1 7.28 NA 1 6 1 
829860A 53 1 14.6 NA 2 6 1 
222289C 67 1 22 NA 1 6 1 
146856(O) 70 1 69 NA 2 6 2 
682132B 71 1 11 NA 2 6 2 
173314C 93 1 63 NA 2 6 2 
167277C 58 1 200 NA 2 6 2 
086023C 78 1 47.9 NA 2 6 2 
166092C 85 1 200 NA 2 5 2 
589411(O) 68 1 12 NA 1 6 1 
628207A 77 2 200 NA 2 6 2 
245789A 65 1 13.3 NA 1 6 1 
718698A 65 1 10.3 NA 2 6 1 
843198B 71 1 24 NA 2 6 1 
710163A 63 1 30.8 NA 2 6 2 
205533C 58 1 17 NA 2 6 2 
197995C 58 1 18.5 NA 1 6 1 
195289C 69 1 19 NA 2 6 1 
183875C 66 1 7.31 NA 1 6 1 
180118C 58 1 6.22 NA 1 6 1 
166283C 65 1 6.3 NA 2 6 1 
095463C 75 1 5.9 NA 1 6 1 
163323C 67 1 200 NA 2 6 2 
145826C 75 1 13.1 NA 2 6 1 
137589C 71 1 7.8 NA 2 6 1 
252005C 67 1 12 NA 1 6 1 
233257C 74 1 56 NA 1 6 2 
834213A 70 1 18 1.2 2 6 1 
286651C 75 1 11.4 2.7 2 6 2 
294039C 61 1 29 1.2 2 6 2 
295020C 86 1 6.9 1.4 2 6 1 
302759C 60 1 150 25 2 6 2 
312049C 51 1 52 9.8 2 6 2 
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064126C 65 1 1 0.12 2 6 1 
179322A 71 1 8 1.2 1 6 1 
338253C 74 1 11 1 2 6 2 
336010C 40 1 2 0.18 2 6 1 
341742C 67 1 2.6 0.6 2 6 1 
349104C 82 1 19 0.7 1 6 1 
361964C 41 1 10.8 1.3 2 6 1 
105209B 66 1 5.4 1.8 2 6 1 
825480B 61 1 20 3.4 1 6 1 
366937C 70 1 0.05 0.05 2 6 1 
376922C 53 1 21.9 4.5 1 6 1 
135516C 62 1 7.6 0.66 2 6 1 
391382C 73 1 24 14.7 2 6 2 
390823C 58 1 5 1.2 1 6 1 
396637C 52 1 5.5 0.7 1 6 1 
377821C 68 1 8.6 1.3 1 6 1 
373618C 67 1 150 25 2 6 2 
390783B 67 2 119 4.7 2 6 2 
761684B 71 1 15 3.2 2 6 2 
349492C 65 1 9.7 0.6 1 6 1 
338875C 58 1 3.5 0.8 1 6 1 
307471B 54 1 33.8 1.3 2 6 2 
334991C 78 2 150 25 1 6 2 
327992C 64 1 2.8 0.28 2 6 1 
322038C 63 1 40.7 1.6 2 6 2 
258007C 72 1 9.5 2.1 2 6 1 
313961C 67 1 7.9 1.3 1 6 1 
295920C 42 1 6.7 2 2 6 1 
299341C 64 1 11.8 1.4 2 6 1 
759247B 56 1 20 1.8 2 6 2 
256103C 66 1 22 1.9 2 6 2 
285310C 57 1 150 25 2 6 2 
281616C 70 1 92 4.6 2 6 2 
277025C 61 1 20 2.7 2 6 1 
847140A 76 1 20 3.4 2 6 1 
050862B 66 1 26 2.4 1 6 1 
243970C 66 1 150 25 2 6 2 
264964C 82 1 102 4.2 2 6 2 
259412C 60 1 4.3 0.3 1 6 1 
463980B 73 2 8 0.9 1 6 1 
200149C 71 1 14 1.2 2 6 2 
255792C 67 1 88 12.7 2 6 2 
 95
254834C 60 1 24.4 5.4 2 6 2 
566423C 63 1 21 2.1 2 6 2 
550729C 70 1 12 2.7 2 6 1 
559730c 64 1 3.1 0.73 2 6 1 
553366c 61 1 5.7 1.9 2 6 1 
541639c 70 1 3.9 0.7 2 6 1 
533446c 66 1 150 25 2 6 2 
522328c 67 1 12.2 3 2 6 1 
383155c 80 1 7.6 2.2 1 6 1 
510966c 70 1 10.1 2.7 2 6 1 
013298b 65 1 28 1 1 6 1 
487962c 63 1 3.7 1 2 6 1 
714759b 70 1 52 8.9 2 6 2 
477615c 53 1 0.4 0.05 2 6 1 
469879c 77 1 23.8 2.1 2 6 2 
137077c 62 2 8.8 0.9 1 6 1 
460333c 47 1 92 2.9 2 6 1 
446457c 58 1 10.2 0.2 1 6 1 
382892c 77 1 4.8 1.2 2 6 1 
427913c 62 1 150 25 2 6 2 
426612c 65 1 150 25 2 6 2 
443542b 79 1 18 3.6 2 6 1 
420590c 70 1 12 1.6 2 6 1 
284147c 66 2 150 25 2 6 2 
565255c 60 1 60 1.15 1 6 1 
559023c 48 1 15.6 1.8 1 6 1 
555987c 75 1 46.7 3.7 2 6 2 
555081c 70 1 3.7 0.58 2 6 1 
552763c 56 1 17.6 2 1 6 1 
538932c 57 1 6.6 0.6 1 6 1 
813575b 64 1 11 0.97 1 6 2 
532342c 56 1 0.65 0.18 2 6 1 
518617c 64 1 71 2.5 2 6 2 
704112b 63 1 21 3.5 1 6 1 
476998c 69 1 0.6 0.1 1 6 1 
058037b 81 1 9.9 1.8 1 6 1 
420590c 72 1 11.4 1.6 2 6 1 
303863b 72 1 1.16 0.16 2 6 1 
505491c 82 1 11.8 5.1 2 6 2 
508171c 55 1 30.5 2.1 2 6 2 
205246c 60 2 8 1.2 1 6 1 
509415c 68 1 150 25 2 6 2 
 96
675313b 59 1 11.4 0.6 1 6 1 
494432c 52 1 7.1 0.4 1 6 1 
495069c 75 1 2.6 0.5 2 6 1 
546666a 40 1 7.3 0.67 1 6 1 
491082c 81 1 150 22 1 6 2 
413098a 68 1 18 5.1 1 6 1 
244416c 67 1 12.7 5.1 1 6 1 
489081c 64 1 6.6 1.6 2 6 2 
484743c 77 1 9.3 3.1 1 6 1 
065109c 75 1 5.5 3.2 2 6 1 
407588b 75 1 31 3.6 2 6 1 
463843c 56 1 6.3 0.8 2 6 1 
461008c 50 1 80 3.7 2 6 2 
453001c 64 1 5.3 0.5 1 6 1 
443277c 63 1 150 25 2 6 2 
437641c 67 1 21 0.76 1 6 2 
433900c 67 1 23.6 2.7 1 6 1 
418157c 62 1 9.7 1.1 2 6 1 
411839c 59 1 13.7 2.5 2 6 1 
674906c 70 1 46 14 2 6 2 
668357c 62 1 18.7 2.35 2 6 2 
659388c 70 1 36.4 19.6 2 6 2 
649277c 67 1 6.5 0.6 1 6 1 
649559c 81 1 150 25 2 6 2 
646229c 61 1 42 1.4 2 6 2 
633060c 63 1 15.2 0.56 2 6 2 
638627c 50 1 2.16 1.1 2 6 1 
634580c 66 1 99 6.9 2 6 2 
631975c 63 1 10.6 0.8 2 6 2 
634316c 73 1 71.5 9.2 2 6 2 
628106c 70 1 7.6 1.2 2 6 1 
182838c 54 1 6.6 0.7 1 6 1 
619770c 58 1 17.5 7.1 2 6 2 
611823c 65 1 9.7 1 1 6 1 
606051c 65 1 7.1 1.5 1 6 1 
607009c 53 1 4.2 0.8 1 6 1 
603636c 62 1 8.7 2.2 1 6 1 
245824c 70 1 9 0.36 2 6 2 
266461c 66 1 1.4 0.3 2 6 2 
586305c 70 1 9.8 0.6 2 6 2 
675313b 58 2 11.4 0.6 1 6 1 
577326c 41 1 150 25 2 6 2 
 97
744521c 60 1 14 2.3 1 6 2 
748443c 65 1 9.36 1.29 1 6 1 
734154c 52 1 7.35 0.48 1 6 1 
732662c 60 1 7.8 0.16 1 6 1 
736191c 60 1 25.7 7.6 1 6 2 
716357c 71 1 31.7 10.5 2 6 2 
533605b 53 1 11.3 2 2 6 2 
697044c 70 1 7 1.6 2 6 1 
675718c 57 1 4.2 0.73 1 6 1 
671839c 56 1 6.19 0.3 2 6 1 
655747c 50 1 29.3 48 2 6 2 
555079c 74 1 87.6 23.4 2 6 2 
629851c 68 1 10.5 1.3 1 6 1 
622023c 69 1 5.4 0.63 2 6 2 
627973c 68 1 150 25 2 6 2 
606580c 61 1 2.35 0.6 2 6 1 
593830c 73 1 42.8 3.2 2 6 2 
597858c 73 1 18.7 2.2 2 6 2 
593966c 76 1 63.9 21.5 2 6 2 
580602c 80 1 150 25 2 6 2 
572104c 46 2 0.86 0.13 1 6 1 
734797c 61 1 150 25 2 6 2 
726898c 68 1 1.56 0.51 2 6 1 
067949c 81 1 31.7 13.6 2 6 2 
712441c 82 1 27.7 4.4 2 6 1 
689723c 71 1 29 7.9 2 6 2 
702524c 60 1 1.5 0.05 2 6 1 
366290c 61 2 29.6 3.5 2 6 2 
495963c 68 1 150 25 2 6 2 
501969a 59 2 46 11.2 2 6 1 
 
 
1. LUTS (Present -1, Absent -2) 
 
2. NA - Not available 
 
3. DRE (Normal -1, abnormal -2) 
 
4. Biopsy report (Normal -1, malignancy -2) 
